Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
Top Cited Papers
- 31 March 2010
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 159 (3), 331-339
- https://doi.org/10.1016/j.ahj.2009.07.035
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic RangeCirculation, 2008
- Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial FibrillationCirculation: Cardiovascular Quality and Outcomes, 2008
- Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke RiskStroke, 2008
- ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial FibrillationCirculation, 2006
- 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor XaBioorganic & Medicinal Chemistry Letters, 2006
- Review of the rebound phenomenon in new anticoagulant treatmentsCurrent Medical Research and Opinion, 2006
- Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trialThe Lancet, 2003
- Present treatment options for atrial fibrillationHeart, 2003
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionThe New England Journal of Medicine, 1993
- Probability of stroke: a risk profile from the Framingham Study.Stroke, 1991